Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.95 USD | +1.01% | -0.19% | +95.11% |
May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.11% | 2.27B | |
+23.37% | 47.02B | |
+49.79% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell